Lasch H G
Postgrad Med J. 1969 Aug;45(526):539-42. doi: 10.1136/pgmj.45.526.539.
Hypocirculation causes hypercoagulability with an increase of Factors V and VIII, and a diminished platelet count. In shock hypercoagulability is followed by hypocoagulability due to loss of Factors I, II, V, VIII and XIII together with thrombocytopaenia and qualitative alterations in platelet properties. This reversal is caused by disseminated intravascular coagulation consuming clotting factors and platelets—consumptive coagulopathy. Fibrin deposits occur in the peripheral vasculature of the viscera and are associated with a rising oxygen debt, and, in clinical situations, with haemorrhagic diathesis, visceral necrosis and irreversible shock. Localization of the microthrombi is under the influence of catecholamines, ACTH and aldosterone. Administration of heparin in clinical shock may prevent the development of consumptive coagulopathy, but is without effect if disseminated intravascular coagulation is already present. Anti-fibrinolytic therapy is contraindicated whereas streptokinase-induced fibrinolysis has experimental and clinical justifications.
微循环灌注不足会导致血液高凝状态,表现为凝血因子Ⅴ和Ⅷ水平升高,血小板计数减少。在休克状态下,血液高凝状态之后会出现低凝状态,这是由于凝血因子Ⅰ、Ⅱ、Ⅴ、Ⅷ和ⅩⅢ丢失,同时伴有血小板减少以及血小板性质的质的改变。这种转变是由弥散性血管内凝血消耗凝血因子和血小板所致,即消耗性凝血病。纤维蛋白沉积在内脏的外周血管中,并与氧债增加相关,在临床情况下,还与出血素质、内脏坏死和不可逆性休克有关。微血栓的定位受儿茶酚胺、促肾上腺皮质激素和醛固酮的影响。在临床休克中使用肝素可能会预防消耗性凝血病的发生,但如果已经存在弥散性血管内凝血则无效。抗纤溶治疗是禁忌的,而链激酶诱导的纤溶有实验和临床依据。